Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WAVE1-siRNA
- Development stage
- Preclinical
- Lead developer
- National Institute of Neurological Disorders and Stroke
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
WAVE1-siRNA is a small interfering RNA (siRNA) designed to silence the expression of WASP-family verprolin homologous protein 1 (WAVE1). WAVE1 is a downstream effector of small GTPases that regulates the actin cytoskeleton and modulates cell motility and morphology. In glioblastoma (GBM), WAVE1 is often upregulated compared to normal brain tissue. By targeting WAVE1 mRNA for degradation, this siRNA inhibits the proliferation, migration, and self-renewal of patient-derived primary GBM neurospheres. Research indicates that WAVE1 knockdown exerts a cytostatic effect rather than an apoptotic one, suggesting its potential as a therapeutic strategy to limit tumor progression and invasiveness in high-grade gliomas.
- Other names
- WASP-family verprolin homologous protein 1 siRNAWAVE1 knockdown siRNAWAVE-1 knockdown siRNAWAVE 1 knockdown siRNA
02
Targets
Wiskott-Aldrich syndrome protein family member 1 (WASF1) mRNA
Beyond the preview
Go deeper on WAVE1-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WAVE1-siRNA.